Abaloparatide
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
L-alanyl-L-valyl-L-seryl-L-α-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-α-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-α-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-L-alaninamide
|
|
Clinical data | |
Legal status |
|
Routes of administration |
Subcutaneous injection |
Identifiers | |
CAS Number | 247062-33-5 |
ATC code | none |
PubChem | CID: 76943386 |
ChemSpider | 34443170 |
UNII | AVK0I6HY2U |
Synonyms | BA058, BIM-44058 |
Chemical data | |
Formula | C174H299N56O49 |
Molecular mass | 3,959.65 g·mol−1 |
|
|
|
Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug in clinical development for treating osteoporosis.[1] Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.[2]
A subcutaneous injection formulation of the drug has completed a Phase III trial for osteoporosis.[3] A transdermal patch is also in development.[2]
Phase II results were encouraging.[4]
References
- ↑ http://www.genengnews.com/gen-news-highlights/radius-raises-26-75m-for-phase-iii-osteoporosis-trial/81245990/
- ↑ 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Clinical trial number NCT01343004 for "Phase III Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women" at ClinicalTrials.gov
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>